Odyssey Therapeutics Posts Corporate Presentation (Sept 2026)

What Happened
Odyssey Therapeutics, Inc. announced under Regulation FD that it posted a corporate presentation to its investor relations website on September 8, 2026. The presentation was furnished as Exhibit 99.1 to a Form 8-K filed with the SEC on September 9, 2026. The Form 8-K was signed by Jason Haas, Chief Financial Officer, dated September 8, 2026.

Key Details

• Date posted: September 8, 2026; Form 8-K filed: September 9, 2026.
• Presentation furnished as Exhibit 99.1 to the Form 8-K.
• The disclosure was made under Item 7.01 (Regulation FD Disclosure).
• Form signed by CFO Jason Haas (dated September 8, 2026).

Why It Matters
A Regulation FD filing means the company shared the presentation publicly to ensure broad, fair disclosure of the information. For investors, the presentation may include updates on strategy, clinical programs, or corporate milestones—information that can affect investor view of the company. Review the posted presentation on Odyssey’s investor site for any new operational or pipeline details; the 8-K itself does not report earnings, executive changes, mergers, or financial results.